PTGXHealthcare · BiotechnologyThe 14 Wall Street analysts covering Protagonist Therapeutics, Inc. hold a median 12-month price target of $177 — +23.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 3 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Protagonist Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Issuance (56): The company has been issuing shares or taking on financing, diluting existing holders.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PTGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +23.0% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Oct 2026 | TD Cowen | Maintains | Buy | $155 → $160 |
| 12 Oct 2026 | Leerink Partners | Assumes | Outperform | $150 → $190 |
| 12 Oct 2026 | UBS | Initiates | Buy | $184 |
| 12 Oct 2026 | UBS | Initiates | Buy | — |
| 1 Sept 2026 | Barclays | Maintains | Overweight | $153 → $180 |
| 1 Sept 2026 | Barclays | Maintains | Overweight | — |
| 1 Sept 2026 | BMO Capital | Maintains | Outperform | — |
| 1 Sept 2026 | BMO Capital | Maintains | Outperform | $178 → $190 |
| 31 Aug 2026 | Citigroup | Maintains | Buy | — |
| 31 Aug 2026 | Citigroup | Maintains | Buy | $175 → $182 |
| 31 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $167 → $170 |
| 31 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Aug 2026 | BMO Capital | Maintains | Outperform | $112 → $178 |
| 17 Aug 2026 | BMO Capital | Maintains | Outperform | — |
| 10 Aug 2026 | Goldman Sachs | Upgrade | Buy | — |
| 10 Aug 2026 | Goldman Sachs | Upgrade | Buy | $110 → $186 |
| 10 Aug 2026 | Truist Securities | Maintains | Buy | $145 → $170 |
| 10 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 10 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 10 Aug 2026 | Wedbush | Maintains | Outperform | $118 → $173 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PTGX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Protagonist Therapeutics, Inc. returned +87.6% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 5% of US stocks
Cheaper than 6% of US stocks
Cheaper than 8% of US stocks
Cheaper than 2% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 88% of US stocks
Higher than 65% of US stocks
Higher than 74% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Protagonist Therapeutics, Inc. has a market value of $9.3B and an enterprise value of $8.3B.
Revenue in the twelve months to 30 June 2026: $282.0M. The latest quarter grew 3749.2% year on year.
Net income over the same four quarters: $82.9M, a 29.4% net margin.
Diluted earnings per share, trailing twelve months: $1.03.
Free cash flow in the twelve months to 30 June 2026: $130.6M.
Trailing P/E: 139.2×; forward P/E: −1444.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Protagonist Therapeutics, Inc. employs 141 people — $2.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Protagonist Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks reports that Protagonist Therapeutics is preparing to report Q3 results, with Wall Street expecting earnings growth. The excerpt says the company lacks the two key ingredients for a likely earnings beat.
Why it matters — PTGX watchers may note the stated earnings-growth expectation alongside Zacks’ view that a beat is not likely.
Zacks Investment Research highlights its Style Scores as a way to identify stocks it describes as strong and market-beating, framing Protagonist Therapeutics (PTGX) as a long-term momentum stock.
Why it matters — PTGX watchers may note the article’s favorable momentum framing and its reference to Zacks Style Scores.
Zacks reports that analysts’ mean price target for Protagonist Therapeutics implies about 25.3% upside. It notes that this metric has not been consistently effective, while analyst agreement on raising earnings estimates indicates potential upside.
Why it matters — PTGX watchers may consider the price-target estimate and the accompanying earnings-estimate trend, while noting Zacks’ caveat about the metric’s reliability.
Protagonist Therapeutics is described as a royalty-driven company with two FDA-approved drugs, robust liquidity and a $300 million buyback. It secured royalties and milestones from Takeda and J&J, with the excerpt highlighting potential annual royalty revenue of $605 million against $220 million in expenses.
Why it matters — The partner arrangements and projected high-margin royalties are presented as drivers of PTGX’s earnings outlook and economic upside.
Protagonist Therapeutics was upgraded to Zacks Rank #1 (Strong Buy), reflecting increased optimism about its earnings prospects. The excerpt says this might drive the stock higher in the near term.
Why it matters — PTGX watchers may note the improved Zacks assessment of the company's earnings prospects.
The 14 Wall Street analysts covering Protagonist Therapeutics, Inc. have a median 12-month price target of $177, with estimates ranging from $149 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Protagonist Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Protagonist Therapeutics, Inc. 98 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Protagonist Therapeutics, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +23.0% from the last close, and Ticker Nerd's factor model ranks Protagonist Therapeutics, Inc. 98 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Protagonist Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $149 to $225 over the next 12 months.
Protagonist Therapeutics, Inc. returned +87.6% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapies for serious diseases.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth". Zacks reports that Protagonist Therapeutics is preparing to report Q3 results, with Wall Street expecting earnings growth. The excerpt says the company lacks the two key ingredients for a likely earnings beat.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapies for serious diseases. Using a proprietary peptide technology platform, the company advances drug candidates designed to address unmet needs in inflammation and immunology, hematology, and metabolic disease. Its current programs center on differentiated medicines such as rusfertide and oral peptide candidates developed for immune-mediated and blood disorders, reflecting a strategy built around targeted mechanisms and convenient routes of administration. Protagonist Therapeutics works across research, clinical development, and collaboration-based programs to create therapies with potential use in conditions where existing treatment options are limited or inadequate. Headquartered in Newark, California, Protagonist Therapeutics plays a specialized role in the biopharmaceutical market by focusing on peptide innovation and translational medicine.
CEO Dr. Dinesh V. Patel Ph.D. · 141 employees · United States · https://www.protagonist-inc.com
